X4 PHARMACEUTICALS, INC Operating Expenses
X4 PHARMACEUTICALS, INC (XFOR) reported Operating Expenses of $37.29 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2024-05-07
- X4 PHARMACEUTICALS, INC operating expenses for the quarter ending 2024-03-31 was $37.29M, a 27.25% increase year-over-year.
- X4 PHARMACEUTICALS, INC operating expenses for the quarter ending 2023-12-31 was $25.20M, a 1.48% decline year-over-year.
- X4 PHARMACEUTICALS, INC operating expenses for the quarter ending 2023-09-30 was $27.21M, a 35.03% increase year-over-year.
- X4 PHARMACEUTICALS, INC operating expenses for the quarter ending 2023-06-30 was $25.80M, a 25.45% increase year-over-year.
- X4 PHARMACEUTICALS, INC operating expenses for fiscal 2023 was $107.52M, a 22.79% increase from fiscal 2022.
- X4 PHARMACEUTICALS, INC operating expenses for fiscal 2022 was $87.57M, a 2.89% increase from fiscal 2021.
- X4 PHARMACEUTICALS, INC operating expenses for fiscal 2021 was $85.11M, a 35.36% increase from fiscal 2020.
- X4 PHARMACEUTICALS, INC operating expenses for fiscal 2020 was $62.87M, a 21.61% increase from fiscal 2019.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | $37.29M 10-Q · filed 2024-05-07 | $62.49M derived: sum of 2 quarters · filed 2024-05-07 | $89.70M derived: sum of 3 quarters · filed 2024-05-07 | $115.51M derived: sum of 4 quarters · filed 2024-05-07 | ||||
| 2023-12-31 | $25.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $52.41M derived: sum of 2 quarters · filed 2024-03-21 | $78.22M derived: sum of 3 quarters · filed 2024-03-21 | $107.52M 10-K · filed 2024-03-21 | ||||
| 2023-09-30 | $27.21M 10-Q · filed 2023-11-09 | $53.02M derived: sum of 2 quarters · filed 2023-11-09 | $82.32M 10-Q · filed 2023-11-09 | $107.90M derived: sum of 4 quarters · filed 2024-05-07 | ||||
| 2023-06-30 | $25.80M 10-Q · filed 2023-08-10 | $55.11M 10-Q · filed 2023-08-10 | $80.69M derived: sum of 3 quarters · filed 2024-05-07 | $100.84M derived: sum of 4 quarters · filed 2024-05-07 | ||||
| 2023-03-31 | $29.30M 10-Q · filed 2024-05-07 | $54.88M derived: sum of 2 quarters · filed 2024-05-07 | $75.03M derived: sum of 3 quarters · filed 2024-05-07 | $95.61M derived: sum of 4 quarters · filed 2024-05-07 | ||||
| 2022-12-31 | $25.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $45.73M derived: sum of 2 quarters · filed 2024-03-21 | $66.30M derived: sum of 3 quarters · filed 2024-03-21 | $87.57M 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | $20.15M 10-Q · filed 2023-11-09 | $40.72M derived: sum of 2 quarters · filed 2023-11-09 | $61.99M 10-Q · filed 2023-11-09 | $91.05M derived: sum of 4 quarters · filed 2024-03-21 | ||||
| 2022-06-30 | $20.57M 10-Q · filed 2023-08-10 | $41.84M 10-Q · filed 2023-08-10 | $70.89M derived: sum of 3 quarters · filed 2024-03-21 | $90.01M derived: sum of 4 quarters · filed 2024-03-21 | ||||
| 2022-03-31 | $21.27M 10-Q · filed 2023-05-04 | $50.32M derived: sum of 2 quarters · filed 2024-03-21 | $69.44M derived: sum of 3 quarters · filed 2024-03-21 | $88.44M derived: sum of 4 quarters · filed 2024-03-21 | ||||
| 2021-12-31 | $29.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $48.17M derived: sum of 2 quarters · filed 2024-03-21 | $67.17M derived: sum of 3 quarters · filed 2024-03-21 | $85.11M 10-K · filed 2024-03-21 | ||||
| 2021-09-30 | $19.12M 10-Q · filed 2022-11-03 | $38.12M derived: sum of 2 quarters · filed 2022-11-03 | $56.05M 10-Q · filed 2022-11-03 | $73.71M derived: sum of 4 quarters · filed 2023-03-21 | ||||
| 2021-06-30 | $19.00M 10-Q · filed 2022-08-04 | $36.93M 10-Q · filed 2022-08-04 | $54.59M derived: sum of 3 quarters · filed 2023-03-21 | $71.57M derived: sum of 4 quarters · filed 2023-03-21 | ||||
| 2021-03-31 | $17.94M 10-Q · filed 2022-05-12 | $35.59M derived: sum of 2 quarters · filed 2023-03-21 | $52.57M derived: sum of 3 quarters · filed 2023-03-21 | $67.23M derived: sum of 4 quarters · filed 2023-03-21 | ||||
| 2020-12-31 | $17.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $34.63M derived: sum of 2 quarters · filed 2023-03-21 | $49.29M derived: sum of 3 quarters · filed 2023-03-21 | $62.87M 10-K · filed 2023-03-21 | ||||
| 2020-09-30 | $16.98M 10-Q · filed 2021-11-04 | $31.64M derived: sum of 2 quarters · filed 2021-11-04 | $45.22M 10-Q · filed 2021-11-04 | $56.09M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2020-06-30 | $14.66M 10-Q · filed 2021-08-03 | $28.24M 10-Q · filed 2021-08-03 | $39.11M derived: sum of 3 quarters · filed 2022-03-17 | $56.09M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2020-03-31 | $13.58M 10-Q · filed 2021-05-06 | $24.46M derived: sum of 2 quarters · filed 2022-03-17 | $41.43M derived: sum of 3 quarters · filed 2022-03-17 | $54.85M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2019-12-31 | $10.88M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $27.85M derived: sum of 2 quarters · filed 2022-03-17 | $41.27M derived: sum of 3 quarters · filed 2022-03-17 | $51.70M 10-K · filed 2022-03-17 | ||||
| 2019-09-30 | $16.98M 10-Q · filed 2020-11-05 | $30.39M derived: sum of 2 quarters · filed 2020-11-05 | $40.83M 10-Q · filed 2020-11-05 | $53.80M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $13.41M 10-Q · filed 2020-08-04 | $23.85M 10-Q · filed 2020-08-04 | $36.82M derived: sum of 3 quarters · filed 2020-08-04 | $45.37M derived: sum of 4 quarters · filed 2020-08-04 | ||||
| 2019-03-31 | $10.44M 10-Q · filed 2020-05-07 | $23.41M derived: sum of 2 quarters · filed 2020-05-07 | $31.95M derived: sum of 3 quarters · filed 2020-05-07 | $38.33M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $12.97M 10-K · filed 2019-03-11 | $21.52M derived: sum of 2 quarters · filed 2019-11-07 | $27.89M derived: sum of 3 quarters · filed 2019-11-07 | $29.09M 10-K · filed 2021-03-19 | $49.38M 10-K · filed 2019-03-11 | |||
| 2018-09-30 | $8.54M 10-Q · filed 2019-11-07 | $12.85M 10-Q · filed 2018-11-09 | $14.92M derived: sum of 2 quarters · filed 2019-11-07 | $21.03M 10-Q · filed 2019-11-07 | $36.41M 10-Q · filed 2018-11-09 | $32.64M derived: sum of 4 quarters · filed 2019-11-07 | ||
| 2018-06-30 | $6.38M 10-Q · filed 2019-08-07 | $12.62M 10-Q · filed 2018-08-13 | $12.49M 10-Q · filed 2019-08-07 | $23.57M 10-Q · filed 2018-08-13 | $24.09M derived: sum of 3 quarters · filed 2019-08-07 | $37.15M derived: sum of 4 quarters · filed 2019-08-07 | ||
| 2018-03-31 | $6.11M 10-Q · filed 2019-05-15 | $10.95M 10-Q · filed 2018-05-10 | $17.72M derived: sum of 2 quarters · filed 2019-05-15 | $30.77M derived: sum of 3 quarters · filed 2019-05-15 | $36.42M derived: sum of 4 quarters · filed 2019-05-15 | |||
| 2017-12-31 | $11.61M 10-K · filed 2019-03-11 | $24.66M derived: sum of 2 quarters · filed 2019-03-11 | $30.31M derived: sum of 3 quarters · filed 2019-03-11 | $22.25M 10-K · filed 2020-03-12 | $36.13M 10-K · filed 2019-03-11 | |||
| 2017-09-30 | $13.06M 10-K · filed 2019-03-11 | $18.70M derived: sum of 2 quarters · filed 2019-03-11 | $24.53M 10-Q · filed 2018-11-09 | |||||
| 2017-06-30 | $5.64M 10-K · filed 2019-03-11 | $11.47M 10-Q · filed 2018-08-13 | ||||||
| 2017-03-31 | $5.83M 10-K · filed 2019-03-11 | |||||||
| 2016-12-31 | $24.35M 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |